Failure of IS-reduction trial after 2-4 weeks (no clinical/radiologic improvement) — esca...

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

ID	`RF-PTLD-TRANSFORMATION-PROGRESSION`
Type	Red flag
Status	reviewed 2026-04-25 \| pending_clinical_signoff
Diseases	`DIS-PTLD`
Sources	`SRC-ESMO-DLBCL-2024` `SRC-NCCN-BCELL-2025`

Red Flag Origin

Definition	Failure of IS-reduction trial after 2-4 weeks (no clinical/radiologic improvement) — escalate to rituximab monotherapy → R-CHOP if rituximab fails.
Clinical direction	intensify
Category	transformation-progression

Trigger Logic

{
  "any_of": [
    {
      "finding": "is_reduction_failure_2_4_weeks",
      "value": true
    },
    {
      "finding": "ptld_progression_on_rituximab",
      "value": true
    }
  ],
  "type": "composite_clinical"
}

Notes

Sequential treatment paradigm in polymorphic PTLD: IS-reduction → rituximab → chemoimmuno. Each escalation is a separate Indication selection downstream of 1L Algorithm.

Used By

No reverse references found in the YAML corpus.